BIIB - RBC starts Lexeo at outperform cites Friedreich's ataxia drug opportunity
2023-11-29 18:23:20 ET
More on Lexeo Therapeutics, Inc.
- Stocks To Watch: Spotlight On OPEC Meeting, Amazon AWS Event, Tesla's Cybertruck Reveal, And Box Office Drama
- Lexeo Therapeutics Proposes Terms For $126 Million IPO
- Lexeo Therapeutics Starts $100 Million U.S. IPO Effort
- Lexeo Therapeutics shares down 8% after downsized $100M IPO
- Genetic therapy developer Lexeo prices IPO at $11.00/ share
For further details see:
RBC starts Lexeo at outperform, cites Friedreich's ataxia drug opportunity